logo

Five Prime Therapeutics (FPRX)



Trade FPRX now with
  Date
  Headline
4/16/2021 8:27:00 AM Amgen Completes Acquisition Of Five Prime Therapeutics For $38/Shr Cash
3/4/2021 8:31:35 AM Amgen To Acquire Five Prime Therapeutics For $38/Shr Cash, Representing An Equity Value Of $1.9 Bln
1/15/2021 6:58:44 AM Five Prime Therapeutics Presents Phase 2 FIGHT Trial Results Of FGFR2b
11/12/2020 10:15:51 PM Five Prime Therapeutics Announces Pricing Of Underwritten Public Offering Of 7.20 Mln Shares At $21.00/shr
11/11/2020 4:04:00 PM Five Prime Announces Proposed Public Offering Of Common Stock
4/14/2020 9:06:44 AM Five Prime Therapeutics Names Thomas Civik As President And CEO
3/13/2020 9:28:28 AM Five Prime Therapeutics Announces Publication Of The Phase 1 Bemarituzumab Study
5/10/2019 8:42:01 AM Wedbush Is Cutting Five Prime Therapeutics (FPRX) FY19 Rev. Estimate To 23.3 M From 24.0 M
5/10/2019 8:41:37 AM Wedbush Is Raising Five Prime Therapeutics (FPRX) FY19 Estimate To -3.74 From -3.75
1/17/2019 6:59:29 AM Wedbush Is Increasing Five Prime Therapeutics (FPRX) FY18 Rev. Estimate To 53.6 M From 53.3 M